{"id":"methotrexate-stable-dose","safety":{"commonSideEffects":[{"rate":"10–30","effect":"Myelosuppression (anemia, leukopenia, thrombocytopenia)"},{"rate":"5–20","effect":"Mucositis / stomatitis"},{"rate":"10–25","effect":"Nausea and vomiting"},{"rate":"5–15","effect":"Hepatotoxicity"},{"rate":"5–10","effect":"Nephrotoxicity"},{"rate":"5–15","effect":"Alopecia"},{"rate":"5–20","effect":"Infection (due to immunosuppression)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting dihydrofolate reductase, methotrexate prevents the conversion of dihydrofolate to tetrahydrofolate, disrupting one-carbon transfer reactions essential for nucleotide synthesis. This leads to suppression of rapidly dividing cells, including cancer cells and activated immune cells. At lower doses used in autoimmune conditions, it also exerts immunosuppressive effects through adenosine release and reduced T-cell proliferation.","oneSentence":"Methotrexate inhibits dihydrofolate reductase, blocking the synthesis of purines and pyrimidines required for DNA replication and cell division.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:46.771Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute lymphoblastic leukemia (ALL)"},{"name":"Osteosarcoma"},{"name":"Breast cancer"},{"name":"Lung cancer"},{"name":"Rheumatoid arthritis"},{"name":"Psoriasis"},{"name":"Crohn's disease"}]},"trialDetails":[{"nctId":"NCT04609046","phase":"PHASE1","title":"Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-24","conditions":"Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System","enrollment":47},{"nctId":"NCT07242092","phase":"PHASE4","title":"Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-03-25","conditions":"Autoimmune Rheumatic Diseases","enrollment":192},{"nctId":"NCT01143337","phase":"PHASE2","title":"Efficacy and Safety Study of MP-435 in Combination With Methotrexate (MTX) in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2010-06","conditions":"Rheumatoid Arthritis","enrollment":112},{"nctId":"NCT06590090","phase":"PHASE2","title":"Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment","status":"NOT_YET_RECRUITING","sponsor":"XBiotech, Inc.","startDate":"2026-07-15","conditions":"Rheumatoid Arthritis","enrollment":108},{"nctId":"NCT05879419","phase":"PHASE4","title":"Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2023-05-23","conditions":"Rheumatoid Arthritis, Spondylitis, Ankylosing, Spondyloarthritis","enrollment":2005},{"nctId":"NCT05428488","phase":"PHASE3","title":"Efficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2022-11-28","conditions":"Rheumatoid Arthritis","enrollment":220},{"nctId":"NCT04435288","phase":"PHASE3","title":"Spondyloarthritis: Inducing Drug-free Remission by Early TNF-alpha Blockade","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2020-08-24","conditions":"Peripheral Spondyloarthritis","enrollment":90},{"nctId":"NCT02629159","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2015-12-01","conditions":"Rheumatoid Arthritis","enrollment":1629},{"nctId":"NCT02303821","phase":"PHASE1","title":"Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-02-16","conditions":"Acute Lymphoblastic Leukemia (ALL)","enrollment":141},{"nctId":"NCT05533372","phase":"PHASE1","title":"MAD Study of IA-14069","status":"RECRUITING","sponsor":"ILAb Co., Ltd.","startDate":"2022-10-10","conditions":"Healthy, Rheumatoid Arthritis","enrollment":75},{"nctId":"NCT04737889","phase":"PHASE2","title":"Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2021-01-13","conditions":"Primary Central Nervous System Lymphoma","enrollment":30},{"nctId":"NCT03254589","phase":"PHASE4","title":"Methotrexate, Blood Pressure and Arterial Function in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Flinders University","startDate":"2017-10-01","conditions":"Rheumatoid Arthritis, Stiffness, Aortic, Endothelial Dysfunction","enrollment":124},{"nctId":"NCT03495960","phase":"PHASE2","title":"Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System","status":"COMPLETED","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2019-06-15","conditions":"Primary Central Nervous System Lymphoma","enrollment":72},{"nctId":"NCT06297096","phase":"PHASE3","title":"Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland","startDate":"2025-01-01","conditions":"Systemic Sclerosis, Interstitial Lung Disease","enrollment":86},{"nctId":"NCT01009242","phase":"PHASE1, PHASE2","title":"To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2009-10","conditions":"Arthritis, Rheumatoid Arthritis","enrollment":40},{"nctId":"NCT03257852","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of ASP5094 in Patients With Rheumatoid Arthritis on Methotrexate","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2017-09-29","conditions":"Rheumatoid Arthritis (RA)","enrollment":66},{"nctId":"NCT02884635","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of ASP1707 in Postmenopausal Female Patients With Rheumatoid Arthritis Taking Methotrexate","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2016-09-16","conditions":"Rheumatoid Arthritis","enrollment":72},{"nctId":"NCT03016013","phase":"PHASE3","title":"A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2017-03-29","conditions":"Moderate and Severe RheumatoId Arthritis","enrollment":479},{"nctId":"NCT05279417","phase":"PHASE2","title":"ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2022-02-01","conditions":"Rheumatoid Arthritis","enrollment":251},{"nctId":"NCT03155347","phase":"PHASE3","title":"An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-08-02","conditions":"Rheumatoid Arthritis","enrollment":340},{"nctId":"NCT03120949","phase":"PHASE3","title":"Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"R-Pharm International, LLC","startDate":"2017-07-04","conditions":"Rheumatoid Arthritis","enrollment":2106},{"nctId":"NCT00579878","phase":"PHASE3","title":"Triple III Comparison of Leflunomide Alone Versus Two DMARD Combinations in the Treatment of Rheumatoid Arthritis","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2001-03-27","conditions":"Rheumatoid Arthritis","enrollment":69},{"nctId":"NCT02760433","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease","status":"COMPLETED","sponsor":"R-Pharm International, LLC","startDate":"2017-01-25","conditions":"Rheumatoid Arthritis","enrollment":368},{"nctId":"NCT02760407","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease","status":"COMPLETED","sponsor":"R-Pharm International, LLC","startDate":"2016-06-06","conditions":"Rheumatoid Arthritis","enrollment":1648},{"nctId":"NCT00101101","phase":"PHASE2","title":"Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2004-07","conditions":"Lymphoma","enrollment":43},{"nctId":"NCT02252042","phase":"PHASE3","title":"Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-11-17","conditions":"Head and Neck Squamous Cell Cancer","enrollment":495},{"nctId":"NCT02270632","phase":"PHASE2","title":"A Randomized, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of F8IL10 (Dekavil) in Patients With Active RA Receiving MTX","status":"TERMINATED","sponsor":"Philogen S.p.A.","startDate":"2014-10-01","conditions":"Rheumatoid Arthritis","enrollment":27},{"nctId":"NCT04247815","phase":"PHASE2","title":"Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2020-03-16","conditions":"Rheumatoid Arthritis","enrollment":25},{"nctId":"NCT03813199","phase":"PHASE2","title":"Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Abivax S.A.","startDate":"2019-07-04","conditions":"Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT04610476","phase":"PHASE3","title":"Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2020-10-19","conditions":"Psoriatic Arthritis, Withdrawal, Reduction","enrollment":270},{"nctId":"NCT05549284","phase":"PHASE2","title":"Orelabrutinib,Rituximab and Methotrexate in Newly-diagnosed Primary Central Nervous System Lymphoma(PCNSL)","status":"RECRUITING","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2022-06-01","conditions":"Primary Central Nervous System Lymphoma","enrollment":36},{"nctId":"NCT02466581","phase":"PHASE4","title":"Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity","status":"UNKNOWN","sponsor":"Karolinska Institutet","startDate":"2015-02-03","conditions":"Rheumatoid Arthritis","enrollment":25},{"nctId":"NCT04124861","phase":"NA","title":"Withdraw Drug in Stable IgG4-Related Disease","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-06-23","conditions":"Autoimmune Diseases","enrollment":138},{"nctId":"NCT00950989","phase":"PHASE2","title":"Brodalumab (AMG 827) in Rheumatoid Arthritis (RA) Participants With Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-12-30","conditions":"Rheumatoid Arthritis","enrollment":252},{"nctId":"NCT01949116","phase":"PHASE2","title":"Safety and Effectiveness of Low-Dose Methotrexate for Reducing Inflammation in HIV-Infected Adults on ARV Medications","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-01-31","conditions":"HIV Infections","enrollment":176},{"nctId":"NCT02874092","phase":"PHASE4","title":"Ticagrelor in Methotrexate-Resistant Rheumatoid Arthritis","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2016-11-15","conditions":"Rheumatoid Arthritis","enrollment":9},{"nctId":"NCT03163966","phase":"PHASE2","title":"A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Rottapharm Biotech","startDate":"2017-10-05","conditions":"Rheumatoid Arthritis, DMARD-naive and Early Disease Patients","enrollment":248},{"nctId":"NCT01651936","phase":"PHASE2","title":"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Participants With Rheumatoid Arthritis (MK-8457-010)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-08-29","conditions":"Rheumatoid Arthritis","enrollment":56},{"nctId":"NCT02889796","phase":"PHASE3","title":"Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-08-30","conditions":"Rheumatoid Arthritis","enrollment":1759},{"nctId":"NCT02873936","phase":"PHASE3","title":"Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-07-27","conditions":"Rheumatoid Arthritis","enrollment":449},{"nctId":"NCT03275025","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Safety and Efficacy of YRA-1909 in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Yungjin Pharm. Co., Ltd.","startDate":"2017-04-01","conditions":"Rheumatoid Arthritis","enrollment":116},{"nctId":"NCT00781469","phase":"","title":"A Study to Evaluate the RNA Signature of Rheumatoid Arthritis From Synovium and Whole Blood","status":"TERMINATED","sponsor":"Imperial College London","startDate":"2008-11","conditions":"Rheumatoid Arthritis","enrollment":29},{"nctId":"NCT00808210","phase":"PHASE2","title":"A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2009-03-05","conditions":"Rheumatoid Arthritis","enrollment":28},{"nctId":"NCT01594333","phase":"PHASE3","title":"Cardiovascular Inflammation Reduction Trial","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2013-04","conditions":"Cardiovascular Disease","enrollment":4786},{"nctId":"NCT02833350","phase":"PHASE2","title":"Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2016-09-09","conditions":"Rheumatoid Arthritis","enrollment":578},{"nctId":"NCT03001219","phase":"PHASE2","title":"A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2016-12-22","conditions":"Rheumatoid Arthritis","enrollment":109},{"nctId":"NCT02265705","phase":"PHASE3","title":"A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-10","conditions":"Rheumatoid Arthritis","enrollment":290},{"nctId":"NCT04066803","phase":"PHASE4","title":"Optimal MTX Dose With Folic Acid Randomized Case-control Trial","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-08-01","conditions":"Rheumatoid Arthritis","enrollment":160},{"nctId":"NCT02309359","phase":"PHASE2","title":"A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Ablynx, a Sanofi company","startDate":"2015-01","conditions":"Rheumatoid Arthritis","enrollment":345},{"nctId":"NCT03028467","phase":"PHASE1, PHASE2","title":"Evaluation of Pharmacokinetics and Safety of GSK3196165 in Combination With Methotrexate in Japanese Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-01-24","conditions":"Arthritis, Rheumatoid","enrollment":15},{"nctId":"NCT02882087","phase":"PHASE2","title":"A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis","status":"TERMINATED","sponsor":"RemeGen Co., Ltd.","startDate":"2015-10","conditions":"Moderate and Severe Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT02387762","phase":"PHASE2","title":"ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2015-04","conditions":"Rheumatoid Arthritis","enrollment":31},{"nctId":"NCT01569152","phase":"PHASE2","title":"Safety and Efficacy of MK-8457 and Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Despite MTX Therapy (P08683, MK-8457-008)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-05-22","conditions":"Rheumatoid Arthritis (RA)","enrollment":82},{"nctId":"NCT01679951","phase":"PHASE2","title":"A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-10-31","conditions":"Rheumatoid Arthritis","enrollment":272},{"nctId":"NCT02312219","phase":"","title":"PET/CT Imaging Companion Study To ACTG A5314","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2014-11","conditions":"HIV, Inflammation, Atherosclerosis","enrollment":35},{"nctId":"NCT02046603","phase":"PHASE3","title":"A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-03-04","conditions":"Rheumatoid Arthritis","enrollment":162},{"nctId":"NCT01941095","phase":"PHASE3","title":"A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-11-20","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT02001987","phase":"PHASE3","title":"A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01","conditions":"Rheumatoid Arthritis","enrollment":139},{"nctId":"NCT02379091","phase":"PHASE2","title":"Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-12-17","conditions":"Rheumatoid Arthritis","enrollment":108},{"nctId":"NCT00580840","phase":"PHASE4","title":"Dosing Flexibility Study in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2007-12","conditions":"Rheumatoid Arthritis","enrollment":333},{"nctId":"NCT02187055","phase":"PHASE4","title":"An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-08","conditions":"Rhematoid Arthritis","enrollment":1152},{"nctId":"NCT01050998","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2010-01-05","conditions":"Rheumatoid Arthritis","enrollment":516},{"nctId":"NCT02076659","phase":"PHASE1","title":"Combination Therapy of F8IL10 and Methotrexate in Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"Philogen S.p.A.","startDate":"2011-09","conditions":"Rheumatoid Arthritis","enrollment":36},{"nctId":"NCT02046616","phase":"PHASE3","title":"A Study of Subcutaneous (SC) Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis (RA) and Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-05-28","conditions":"Rheumatoid Arthritis","enrollment":133},{"nctId":"NCT02578511","phase":"PHASE1","title":"Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR)","status":"WITHDRAWN","sponsor":"Ehab L Atallah","startDate":"2017-06-29","conditions":"Acute Lymphoblastic Leukemia in Complete Remission, Lymphoblastic Lymphoma in Complete Remission, Mixed Phenotype Acute Leukemia in Complete Remission","enrollment":""},{"nctId":"NCT01995201","phase":"PHASE3","title":"A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) as Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-09","conditions":"Rheumatoid Arthritis","enrollment":401},{"nctId":"NCT00718718","phase":"PHASE2","title":"A Study of Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2008-08-11","conditions":"Arthritis, Rheumatoid","enrollment":187},{"nctId":"NCT01855789","phase":"PHASE3","title":"A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-11-07","conditions":"Rheumatoid Arthritis","enrollment":718},{"nctId":"NCT01063062","phase":"PHASE3","title":"A Study With Tocilizumab [RoActemra/Actemra] Monotherapy or in Combination With Methotrexate in Patients With Rheumatoid Arthritis (PICTURE)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-02-28","conditions":"Rheumatoid Arthritis","enrollment":107},{"nctId":"NCT01764997","phase":"PHASE3","title":"An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate","status":"TERMINATED","sponsor":"Sanofi","startDate":"2013-04","conditions":"Rheumatoid Arthritis","enrollment":776},{"nctId":"NCT01941940","phase":"PHASE3","title":"A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-09-05","conditions":"Rheumatoid Arthritis","enrollment":227},{"nctId":"NCT00686868","phase":"PHASE1","title":"Study to Evaluate SC Route of Administration of Ofatumumab in RA Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-06-13","conditions":"Arthritis, Rheumatoid","enrollment":35},{"nctId":"NCT01987479","phase":"PHASE3","title":"A Study on Safety and Efficacy of Tocilizumab (RoActemra/Actemra) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01-30","conditions":"Rheumatoid Arthritis","enrollment":150},{"nctId":"NCT00299130","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2005-10","conditions":"Rheumatoid Arthritis","enrollment":511},{"nctId":"NCT01118013","phase":"PHASE2","title":"Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant","status":"TERMINATED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2010-12","conditions":"Leukemia, Lymphoma, Lymphoproliferative Disorder","enrollment":6},{"nctId":"NCT02093026","phase":"PHASE2","title":"Extension Study to Assess the Efficacy and Safety of Repeat Treatment With Rituximab (MabThera) in Participants With Active Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2002-08","conditions":"Rheumatoid Arthritis","enrollment":465},{"nctId":"NCT02097745","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-06","conditions":"Rheumatoid Arthritis","enrollment":341},{"nctId":"NCT01225393","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2010-11","conditions":"Rheumatoid Arthritis","enrollment":211},{"nctId":"NCT00316771","phase":"PHASE2","title":"A Study of P38 Inhibitor (4) in Patients With Active Rheumatoid Arthritis (RA) on Stable Methotrexate Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-11","conditions":"Rheumatoid Arthritis","enrollment":374},{"nctId":"NCT01878318","phase":"PHASE4","title":"A Study of The Effect of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate on Articular Damage in The Hand in Patients With Moderate to Severe Rheumatoid Arthritis Who Have an Inadequate Response to Non-Biological DMARDs","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2013-06","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT01715896","phase":"PHASE2","title":"A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2013-03","conditions":"Rheumatoid Arthritis","enrollment":215},{"nctId":"NCT01661140","phase":"PHASE4","title":"A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2012-09","conditions":"Rheumatoid Arthritis","enrollment":427},{"nctId":"NCT01706926","phase":"PHASE2","title":"A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2012-08","conditions":"Rheumatoid Arthritis","enrollment":420},{"nctId":"NCT02878161","phase":"PHASE4","title":"Predictability Studies on the Efficacy of TNF-α Inhibitors in Chinese RA From \"Real World\"","status":"UNKNOWN","sponsor":"Fen Li","startDate":"2016-01","conditions":"Rheumatoid Arthritis","enrollment":240},{"nctId":"NCT01390441","phase":"PHASE1","title":"A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-07","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT02779114","phase":"PHASE3","title":"RETRO (REduction of Therapy in RA Patients in Ongoing Remission)","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2009-01","conditions":"Rheumatoid Arthritis","enrollment":318},{"nctId":"NCT02720120","phase":"PHASE1, PHASE2","title":"A Study of Ocrelizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA)","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2005-10","conditions":"Rheumatoid Arthritis","enrollment":175},{"nctId":"NCT01909427","phase":"PHASE2","title":"An Efficacy And Safety Study of CNTO 6785 In Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-06","conditions":"Rheumatoid Arthritis","enrollment":257},{"nctId":"NCT01590459","phase":"PHASE2","title":"24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2012-04","conditions":"Rheumatoid Arthritis","enrollment":359},{"nctId":"NCT00928512","phase":"PHASE2","title":"Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-07","conditions":"Rheumatoid Arthritis","enrollment":237},{"nctId":"NCT00298272","phase":"PHASE2","title":"Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Biogen","startDate":"2006-05","conditions":"Rheumatoid Arthritis","enrollment":54},{"nctId":"NCT00462072","phase":"PHASE4","title":"Centocor Microarray Study of Patients","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2007-03","conditions":"Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis","enrollment":31},{"nctId":"NCT00547521","phase":"PHASE3","title":"Phase IIIB Subcutaneous Abatacept Monotherapy Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-12","conditions":"Rheumatoid Arthritis (RA)","enrollment":119},{"nctId":"NCT01481493","phase":"PHASE2","title":"Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)","status":"COMPLETED","sponsor":"Biotest","startDate":"2010-12","conditions":"Rheumatoid Arthritis","enrollment":127},{"nctId":"NCT01235507","phase":"PHASE3","title":"A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) (ALABASTER)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-02","conditions":"Rheumatoid Arthritis","enrollment":71},{"nctId":"NCT02196480","phase":"PHASE4","title":"23-valent Polysaccharide Pneumococcal Vaccine in Juvenile Idiopathic Arthritis Patients Under Anti-TNF Therapy","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2008-01","conditions":"Juvenile Idiopathic Arthritis","enrollment":27},{"nctId":"NCT00424346","phase":"PHASE2","title":"Efficacy, Safety and Tolerability of ACZ885 in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-11","conditions":"Rheumatoid Arthritis","enrollment":274},{"nctId":"NCT01850680","phase":"PHASE1","title":"Single Ascending Dose Study of Safety and Tolerability of Sarilumab and Methotrexate in Japanese Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-04","conditions":"Rheumatoid Arthritis","enrollment":61},{"nctId":"NCT00973479","phase":"PHASE3","title":"An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2009-09","conditions":"Arthritis, Rheumatoid","enrollment":592},{"nctId":"NCT00896168","phase":"PHASE4","title":"An Efficacy and Safety Study of Infliximab in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Xian-Janssen Pharmaceutical Ltd.","startDate":"2007-06","conditions":"Arthritis, Rheumatoid","enrollment":234}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":79,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Methotrexate (stable dose)","genericName":"Methotrexate (stable dose)","companyName":"Hoffmann-La Roche","companyId":"hoffmann-la-roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Methotrexate inhibits dihydrofolate reductase, blocking the synthesis of purines and pyrimidines required for DNA replication and cell division. Used for Acute lymphoblastic leukemia (ALL), Osteosarcoma, Breast cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}